INO: VOCERYQ wins accelerated approval; 7 of 26 patients achieved 12-month complete response

What happened

The FDA granted accelerated approval to VOCERYQ to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP). In the RRP-001 study, 7 of 26 patients achieved a complete response at 12 months, and a confirmatory study is expected.

Confirmed

Global impact / market context

Approval gives VOCERYQ a path to be used for the stated purpose, potentially creating sales for its maker if patients and clinicians adopt it. The small study result and expected confirmatory study leave commercial uptake and the durability of the evidence uncertain.

Analyst inference

For investors in Inovio Pharma, the approval and patient response result may shape expectations for product revenue, but the article gives no sales forecast, pricing, or launch details. A confirmatory study could strengthen or weaken confidence in continued use and future sales.

Analyst inference

What to watch

1. Details on the confirmatory study, including its timing and results, could clarify whether the 12-month complete responses are supported in a larger or longer evaluation. Analyst inference
2. Evidence of patient and clinician uptake, and any disclosed pricing or sales information, would help show whether approval translates into meaningful revenue for Inovio. Analyst inference
3. The article says the FDA granted accelerated approval and that a confirmatory study is expected; it does not specify study timing or commercial launch details. Confirmed

Evidence

• Original source link unavailable